Potential Side Effects and Limited Long-Term Safety Data Potential side effects and limited long-term safety data are restraining the growth of the GLP-1 targeted peptide weight loss drugs market
doi: 10.1001/jamahealthforum.2024.3685 122 RaunK.von VossP.GotfredsenC
Hims executives, including the Chief Executive Officer and Chief Legal Officer, have sold more than 1.7 million shares, realizing $26.4 million of net proceeds since their announcement on May 20 that Hims will sell GLP-1 knockoffs
The GIP component may serve a double function, promoting additional satiety while suppressing some of the nausea caused by GLP-1
Athletes looking to amplify this signal may benefit from timing injections approximately 30-60 minutes before training sessions, a practice analogous to pre-exercise peptide protocols used with BPC-157 and TB-500, though direct timing data for MOTS-c are not yet available in peer-reviewed literature
Its a classic battle of targeted precision versus a comprehensive, multi-pronged approach